Evidence map›Paper›PMID 40871100›Full record

ArticlePharmaceutics2025

Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children.

Safaa Bazbaz, Irina Zaidman, Ehud Even-Or, Polina Stepensky, Razan Sakran, Daniel Kurnik, Gefen Aldouby-Bier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Safaa BazbazDepartment of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.Box 12272, Jerusalem 9112102, Israel.
Irina ZaidmanHadassah Medical Center, Faculty of Medicine, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, P.O.Box 12000, Jerusalem 91120, Israel.
Ehud Even-OrHadassah Medical Center, Faculty of Medicine, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, P.O.Box 12000, Jerusalem 91120, Israel.ORCID 0000-0002-4292-6376
Polina StepenskyHadassah Medical Center, Faculty of Medicine, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, P.O.Box 12000, Jerusalem 91120, Israel.
Razan SakranClinical Pharmacology and Toxicology Section, Rambam Health Care Campus, P.O.Box 9602, Haifa 3109601, Israel.
Daniel KurnikClinical Pharmacology and Toxicology Section, Rambam Health Care Campus, P.O.Box 9602, Haifa 3109601, Israel.ORCID 0000-0002-8462-7673
Gefen Aldouby-BierDepartment of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.Box 12272, Jerusalem 9112102, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

busulfanconditioning therapyhematopoietic stem cell transplantationmodel-informed precision dosingpediatricspharmacokineticssinusoidal obstruction syndrometherapeutic drug monitoring

Identifiers

PMID40871100
PMCPMC12389012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.